scholarly journals An Unusual Case of Vomiting Caused by Myeloid Sarcoma

Reports ◽  
2019 ◽  
Vol 2 (1) ◽  
pp. 2
Author(s):  
Vivek Chand Goodoory ◽  
Diana Triantafyllopoulou ◽  
Ioannis Gkikas ◽  
Fouad Alani ◽  
Ayub Ali Bin ◽  
...  
Keyword(s):  
Mesenteric Artery ◽  
Low Dose ◽  
Unusual Case ◽  
Myeloproliferative Neoplasm ◽  
Myeloid Sarcoma ◽  
Significant Weight Loss ◽  
Proximal Small Bowel ◽  
Coeliac Trunk ◽  
Low Dose Cytarabine ◽  
Bone Marrow Disorder

Myeloid sarcoma is an extramedullary mass consisting of myeloblasts that may present simultaneously or precede a bone marrow disorder. It has been reported to occur without a known preexisting diagnosis of acute leukemia, myelodysplastic syndrome or a myeloproliferative neoplasm and this is known as primary myeloid sarcoma. Here, we report a case of an 80-year-old male who presented with intermittent vomiting and significant weight loss for 3 months. The imaging and histological findings were consistent with a mesenteric myeloid sarcoma encasing the coeliac trunk and superior mesenteric artery, abutting and obstructing the proximal small bowel, causing subacute bowel obstruction. Systemic chemotherapy with low dose cytarabine achieved a reduction in the size of myeloid sarcoma and improved patient’s symptomatology but unfortunately our patient succumbed to progression 11 months later.

scholarly journals An Unusual Case of FIP1L1-PDGFRA Fusion Gene-Positive Myeloproliferative Neoplasm Initially Presenting as Intratechal Myeloid Sarcoma

2014 ◽  
Vol 142 (suppl_1) ◽  
pp. A110-A110
Author(s):  
Richard Koenig ◽  
Vishnu Reddy ◽  
Deniz Peker
Keyword(s):  
Unusual Case ◽  
Fusion Gene ◽  
Myeloproliferative Neoplasm ◽  
Myeloid Sarcoma

scholarly journals Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

2021 ◽  
Author(s):  
Michael Heuser ◽  
B. Douglas Smith ◽  
Walter Fiedler ◽  
Mikkael A. Sekeres ◽  
Pau Montesinos ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Phase Ii ◽  
Clinical Benefit ◽  
Myeloid Leukemia ◽  
Low Dose ◽  
De Novo ◽  
Secondary Acute Myeloid Leukemia ◽  
Low Dose Cytarabine ◽  
Acute Myeloid

AbstractThis analysis from the phase II BRIGHT AML 1003 trial reports the long-term efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized (2:1) patients to receive glasdegib + LDAC (de novo, n = 38; secondary acute myeloid leukemia, n = 40) or LDAC alone (de novo, n = 18; secondary acute myeloid leukemia, n = 20). At the time of analysis, 90% of patients had died, with the longest follow-up since randomization 36 months. The combination of glasdegib and LDAC conferred superior overall survival (OS) versus LDAC alone; hazard ratio (HR) 0.495; (95% confidence interval [CI] 0.325–0.752); p = 0.0004; median OS was 8.3 versus 4.3 months. Improvement in OS was consistent across cytogenetic risk groups. In a post-hoc subgroup analysis, a survival trend with glasdegib + LDAC was observed in patients with de novo acute myeloid leukemia (HR 0.720; 95% CI 0.395–1.312; p = 0.14; median OS 6.6 vs 4.3 months) and secondary acute myeloid leukemia (HR 0.287; 95% CI 0.151–0.548; p < 0.0001; median OS 9.1 vs 4.1 months). The incidence of adverse events in the glasdegib + LDAC arm decreased after 90 days’ therapy: 83.7% versus 98.7% during the first 90 days. Glasdegib + LDAC versus LDAC alone continued to demonstrate superior OS in patients with acute myeloid leukemia; the clinical benefit with glasdegib + LDAC was particularly prominent in patients with secondary acute myeloid leukemia. ClinicalTrials.gov identifier: NCT01546038.

Low-dose cytarabine sets the bar for treatment of elderly with AML

2007 ◽  
Vol &NA; (1585) ◽  
pp. 12
Author(s):  
&NA;
Keyword(s):  
Low Dose ◽  
Low Dose Cytarabine

scholarly journals An unusual case of colon vascularization by the inferior mesenteric artery

2017 ◽  
Vol 16 (1) ◽  
pp. 52-55 ◽  
Author(s):  
Serghei Covanțev ◽  
Natalia Mazuruc ◽  
Olga Belic
Keyword(s):  
Small Intestine ◽  
Superior Mesenteric Artery ◽  
Sigmoid Colon ◽  
Rare Variant ◽  
Mesenteric Artery ◽  
Inferior Mesenteric Artery ◽  
Unusual Case ◽  
Human Anatomy ◽  
Colon And Rectum ◽  
University Department

Abstract In this article we present a rare variant in which the large intestine was vascularized by the inferior mesenteric artery. It was encountered during macro and microscopic dissection of the cadaver of a 63-year-old woman at a university department of human anatomy. In this case, the ascending, transverse, descending, and sigmoid colon and rectum were vascularized by the inferior mesenteric artery, whereas the small intestine, cecum and appendix were supplied by the superior mesenteric artery.

Sign in / Sign up

Export Citation Format

Share Document